Orthovita, Inc. (NASDAQ: VITA), a novel spine/orthopaedic surgical biomaterials company, is focused on providing progressive bone regeneration and soft tissue healing technologies. The company’s expertise lies in developing and distributing novel, high-tech, synthetic-based biomaterial products. Currently, Orthovita has several key commercial product platforms including: Vitoss Bone Graft Substitute, Vitagel Surgical Hemostat, Cortoss Synthetic Cortical Bone, and Imbibe Delivery and Disposable Systems. For further information, visit the Company’s web site at www.orthovita.com.
- 17 years ago
QualityStocks
Orthovita, Inc. (NASDAQ: VITA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Signs MOU to Advance Quantum Computing in South Korea
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced…
-
QualityStocksNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) to Deploy Fingerprint Drug Testing System Across MWS Sites in Australia
Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a leading Australian waste…
-
SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Among Early Adopters of Bitcoin Treasury Strategies Amid Growing Trend
SolarBank Corporation joins a group of 61 public companies adopting bitcoin treasury strategies. The company…